

FDI**Publication: Domain-B****Edition: Online****Date: December 3, 2013****Headline: [No no-compete clause in pharma sector takeovers: govt news](#)**

Synopsis: The government has clarified that the cabinet decision to allow 100-per cent foreign direct investment in existing pharmaceutical units is subject to the condition that there will be no 'no-compete' clause in such takeovers. This means that the promoters of the company would be free to invest in a similar pharma unit after the sale of the existing unit. The cabinet on Thursday decided not to alter the current policy of allowing 100 per cent foreign investment in the pharmaceutical sector

Patents / Intellectual Property Rights / Compulsory Drug Licensing**Publication: Daily News and Analysis****Edition: National****Date: December 2, 2013****Headline: [Pharmaceuticals: Compulsory licensing & reasonable efforts](#)**

Synopsis: Globally harmonised patenting laws recognise the sovereignty of nations like India which retain the right to compulsory licensing. This is in case the patent holder does not manufacture sufficient quantity of drugs, as demanded by the market or doesn't sell it at a reasonable price. A compulsory license can be granted by the government to a domestic pharmaceutical company with desired competence to manufacture patented drugs. But, there is a prerequisite. The domestic company first has to make reasonable efforts to get a voluntary license from the patent holder. In the absence of evidence of making such reasonable efforts, the applicant's right to seek a compulsory license is not triggered.

Publication: MoneyControl**Edition: National****Date: December 2, 2013****Headline: [Revival in export demands to help pharma](#)**

Synopsis: India Ratings & Research (Ind-Ra) expects the tentative revival of global demand to benefit pharmaceutical companies the most, followed by textiles and IT companies. Ind-Ra believes exports of pharmaceuticals from India will continue to witness fast-paced growth driven by patent expiries, higher healthcare spending and demand from new markets such as Europe and Japan.

FDA / Drug Regulatory / DCGI / Pharma Policy**Publication: Business Standard****Edition: National****Date: December 2, 2013****Headline: [Gujarat pharma firms vie for share in cancer drug space](#)**

Synopsis: As the anti-cancer drug market in India, estimated to be around Rs 2,000 crore in 2013, is slated to grow to Rs 3,881 crore by FY17, pharma companies are rushing to cash in on the segment. Reflecting the global trend wherein pharma majors are trying to have enough cancer-fighting drugs in their pipeline, several Gujarat-based companies too have upped their ante to come up with new products in the segment. Companies like Zydus Cadila, Intas Pharma and Cadila Pharmaceuticals have come up with cancer drugs in the recent times. A Mumbai-based analyst said that "While for companies this means higher revenues, for patients too, it would mean more affordable

drugs."

Publication: Outlook India

Edition: Online

Date: Print Edition - December 7, 2013

Journalist: Dawid Bilski - Interview with Timothy C Draper, Founder, Draper Fisher Jurvetson

Headline: ["What I Really Love Is An Idea That Could Take Down A Big Icon"](#)

Synopsis: Timothy Draper said "There should also be a private Food and Drugs Administration (FDA) that it is something people can trust. Somebody could make a fortune on an approval for a new drug. They could do the work that the FDA says it does. They can do it without filling forms that will fill up an entire room. Perhaps it could be more personalised too. We are not making much progress in this sector, at least in the US because of government constraints."

Publication: Zee News

Edition: National

Date: December 2, 2013

Headline: [Delhi Assembly Elections: Political parties come up with interesting promises](#)

Synopsis: In their fight for supremacy in the Delhi Assembly elections, Congress, BJP and Aam Aadmi Party (AAP) are trying to woo voters with some interesting assurances in varied fields. The party has further promised to implement "Essential Drug Policy", considered to be the pet project of Chief Ministerial candidate Harsh Vardhan, and have a system of mobile OPDs in weaker section colonies.

Publication: Pharmabiz

Edition: Online

Date: December 3, 2013

Headline: [Health ministry to create research unit to provide info on removal of hazardous & irrational drugs from market](#)

Synopsis: The Union health ministry will soon create a research unit which will provide the much needed research-based information to the ministry for the removal of hazardous and irrational drugs from the pharmaceutical market in the country. The creation of a research unit within the CDSCO is significant as the ministry had already taken a decision to remove all the hazardous and irrational drugs from the pharmaceutical market in the country. In this connection, the ministry will soon constitute a 'special expert committee' which will review all drug formulations in the market and identify drugs which are potentially hazardous and/or of doubtful therapeutic efficacy.

Drug Pricing

Publication: Mint

Edition: National

Date: December 3, 2013

Opinion: Sakthivel Selvaraj is a health economist with the Public Health Foundation of India.

Headline: [Drug Pricing Conundrum](#)

Synopsis: For over a year, the Indian government has been mulling over the precise methodology for fixing ceiling prices for essential medicines. With debates surrounding drug pricing heating up, this question has now gained the spotlight.

Publication: The Hindu Business Line

Edition: National

Date: December 3, 2013

Headline: [Kerala drug traders press for higher profit margin](#)

Synopsis: Seeking changes in the profit margins for drug dealers announced in the Drug Price Control Order 2013, the All Kerala Druggists and Chemists Association is planning a dharna in front of the State Secretariat on December 4. A.N. Mohan, president of the association, said the DPCO had drastically reduced the profit margins of both retailers and wholesalers and that this put the trade at risk of closure. "We want the Central Government to restore the profit margin structure of the 1995 DPCO," Mohan said. "The dharna is to force the State government to take up the issue with the Centre."

Clinical Trials

Publication: MoneyControl

Edition: Online

Date: December 2, 2013

Headline: [Cadila to launch new affordable lung cancer drug soon](#)

Synopsis: The drug named Mycidac-C is competitively priced at Rs 40,000 for a 10-course injection. It is much cheaper than other similar drugs in the market, which could help take the drug global. Rajiv Modi, cmd of Cadila Pharma says we have completely de-risked the product and have conducted a fairly large clinical trial in India. But for making regulatory submissions in large markets like US, EU, Japan we are looking for a global oncology player who has more experience and expertise to take forward the global clinical trials and filings for this drug.

Publication: VC Circle

Edition: Online

Date: December 2, 2013

Headline: [Vyome Biosciences announces clinical trial results for first product](#)

Synopsis: Delhi-based Vyome Biosciences Pvt Ltd, a biopharma firm which makes pharmaceutical and consumer care products for skin conditions, announced clinical trial results for its first product which is a hair serum formulation.

General Industry

Publication: The Times of India

Edition: National

Date: December 2, 2013

Headline: [Cadila join hands with UK's Helperby to develop potent antibiotics to tackle resistance](#)

Synopsis: Cadila Pharmaceuticals Limited and UK-based antibiotics discovery company Helperby Therapeutics have signed a joint agreement on antibiotic drug resistance research and development. Global market size of antibiotics is estimated to be around \$69 billion.

Publication: Mint

Edition: National

Date: December 2, 2013

Headline: [Glenmark appoints new head for global API and US generic businesses](#)

Synopsis: Glenmark Pharmaceuticals Ltd. said on Monday that it had named Philip Andrew Gioia as president of its business in North America and also the global bulk drug (active pharma ingredients) business. Gioia has already taken charge of his responsibilities and will be reporting to chairman and managing director Glenn Saldanha from the US.

Publication: Pharmabiz

Edition: National

Date: December 3, 2013

Headline: [Biotech, genomics & cancer research common areas of interest between India & Germany: German](#)

[delegation](#)

Synopsis: Biotechnology, genomics and cancer research would be the common areas of interest for R&D and collaborative research between India and Germany, opined trade experts and scientists from Germany who were part of the German trade delegation which was in Mumbai recently. Germany has a good R&D base with big potential in the form of academia industry synergies. Elaborates Dr Rainer Muller, senior manager, Nanotechnology, Germany Trade and Invest, "Drug delivery is highly relevant for the future and efforts are being made particularly in cancer research to find the root of disease through better diagnosis which will ensure its early prevention."

Publication: MoneyLife

Edition: Online

Date: December 2, 2013

Headline: [Fear is the silent killer!](#)

Synopsis: Fear mongering is the norm. People get sick because of the fear instilled by advertising. This provides fodder for pharmaceutical companies to sell drugs. In our present 'health SCARE system', we do not want to be left behind in the advertisement field. Come winter and we are out with the flu vaccine-scare mongering advertisements. Scientific studies have shown that flu vaccine is not effective in the first place and it might even increase the risk of catching flu. But every winter season we are frightened and we want to be vaccinated. Even the World Health Organisation (WHO) was linked to giant pharma lobby in the Swine Flu saga a couple of years ago, when the former unscientifically permitted the tag of 'PANDEMIC' to the disease just to help the vaccine manufacturers to get good business, especially from all the governments all over the world. 'Disease mongering' has become a routine in our medical establishment.

Access and Affordability

Publication: The Times of India

Edition: National

Date: December 2, 2013

Headline: [More HIV patients get access to quality, affordable treatment](#)

Synopsis: The availability of high quality, affordable and patient friendly ARVs has played a vital role in combating the spread of the epidemic in India even as the world still seeks a vaccine and cure for HIV/AIDS. The new therapies in the form of Fixed Dose Combinations (FDCs) have become better, more effective, easier to take and easier to tolerate thus improving patient compliance. Patients are paying seven times less amount for these drugs and combinations compared to a decade ago when handful of multinational companies manufactured and supplied such lifesaving drugs.

Publication: The New Indian Express

Edition: National

Date: December 2, 2013

Headline: [NDPS Bill to Help over A Million: Experts](#)

Synopsis: With the Narcotic Drugs and Psychotropic Substances (NDPS) Act, Amendment Bill hanging in the Parliament, pain and palliative care experts have called upon the Government to ensure its passage during the ensuing winter session. The Indian Association of Palliative Care (IAPC) that has spearheaded institutionalisation of pain and palliative care in the hospitals and medical streams in the country has launched a campaign to sensitise and motivate the Ministers, MPs across all parties to take up the issue so that it "does not get lost in the mass of items". The licences are for very short period and by the time they actually lay hand on the medicines, the permit period is almost on the verge of lapsing. Thus, they buy very small quality as a result of which deserving patients are deprived of the highly effective pain relief medications, former IAPC president and head of Anaesthesiology, Pain and Palliative Care at AIIMS Bhubaneswar, Prof Sukdev Nayak said. By making highly effective and affordable options available, we will be doing great service to such people", Nayak said.